TSL Thinksmart Limited

RNS Number:9651U
Tissue Science Laboratories PLC
04 February 2004

                                                                04 February 2004


                     TSL to Manufacture and Supply Two New
                          Urology/Gynaecology Products


Aldershot, UK - Tissue Science Laboratories plc (LSE: TSL), the medical devices
company, today announced its agreement with C.R. Bard, Inc. to manufacture for
Bard two new urology/gynaecology products, the PelviLaceTM Biourethral Support
System and PelviSoftTM BioMesh.

TSL and Bard have worked together in the pelvic floor reconstruction market
since the launch of Pelvicol(R) Porcine Acellular Collagen Matrix in Europe in
2000 and the US in 2001.  Pelvicol is used by surgeons in a variety of
procedures to treat conditions such as vaginal prolapse and urinary
incontinence, which are commonly caused by childbirth.  It is estimated that
between 300,000 and 400,000 pelvic floor reconstruction procedures are performed
each year in the US, with a similar number performed throughout the rest of the
world.

Martin Hunt, CEO of TSL, said:  "TSL has worked successfully with Bard in the
urology and gynaecology market since 2000 and the manufacture of these two new
products demonstrates the strength of our working relationship.  Our core
Permacol technology can be adapted for use in different surgical applications
and we will continue to look for new markets where the attributes of our
technology can either be differentiated from existing products or where no
satisfactory alternative option currently exists."

                                     -Ends-



Enquiries:

TSL plc                                                  Tel:     01252 333 002
Martin Hunt, Chief Executive
David Jennings, Finance Director

Hogarth PR                                               Tel:     07767 66 00 40
Melanie Toyne-Sewell



Notes to Editors

Background on TSL

Founded in 1995 with headquarters in Aldershot, Hampshire, TSL is a medical
technology company specialising in tissue repair and replacement with a
proprietary sheet product derived from porcine dermis. TSL has launched
successfully different formulations of the product and built a development
pipeline that addresses the large and fast growing surgical implant market.  The
Company floated in November 2001 and is listed on the Alternative Investment
Market.

TSL has a family of products based on the same core technology.  Each product
has been adapted, with unique properties, to make it suitable for use in
different applications.  PelvicolTM/Permacol Surgical Implant (SI) is sold by
Bard in the US and Europe for urology and gynaecology applications; Permacol SI
(general surgery) is sold for complex hernia repair in the US and Europe;
Permacol SI (ENT, plastic and reconstruction) is sold in Europe for head and
face applications; Permacol Injection (UBA) is an injectable form of Permacol
used as a urethral bulking agent to treat female stress incontinence.  The
Company has also recently signed a worldwide distribution agreement with Zimmer
for the application of Permacol (SI) in the orthopaedic market.  Further
variations of the sheet and injectable forms of Permacol are being developed.

Bard is a trademark of C.R. Bard, Inc. or an affiliate.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

PRLUUUWAPUPCGAW

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Lug 2023 a Lug 2024